期刊
CHEMMEDCHEM
卷 16, 期 6, 页码 1034-1046出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.202000841
关键词
inhibitors; medicinal chemistry; myeloid leukemias; STAT5; Suzuki coupling
资金
- Region Centre - Val de Loire
- Fondation pour la Recherche Medicale (FRM) [DCM20181039564]
- Laboratory of excellence Labex SYNORG [ANR-11-LABX-0029]
- La Ligue Contre le Cancer
The researchers synthesized analogs of molecule 17 f and found two compounds, 7 a and 7 a', to have higher antileukemic effects in AML and CML cell lines, demonstrating more efficient inhibition of STAT5 activity/expression and chemoresistance compared to 17 f.
Signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are two closely related STAT family members that are crucial downstream effectors of tyrosine kinase oncoproteins such as FLT3-ITD in acute myeloid leukemia (AML) and BCR-ABL in chronic myeloid leukemia (CML). We recently developed and reported the synthesis of a first molecule called 17 f that selectively inhibits STAT5 signaling in myeloid leukemia cells and overcomes their resistance to chemotherapeutic agents. To improve the antileukemic effect of 17 f, we synthesized ten analogs of this molecule and analyzed their impact on cell growth, survival, chemoresistance and STAT5 signaling. Two compounds, 7 a and 7 a', were identified as having similar or higher antileukemic effects in various AML and CML cell lines. Both molecules were found to be more effective than 17 f at inhibiting STAT5 activity/expression and suppressing the chemoresistance of CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据